Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
IRD
IRD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IRD News
Opus Genetics Aligns with FDA on Phase 3 Study for LCA5 Treatment
2d ago
Newsfilter
Opus Genetics Aligns with FDA on Phase 3 Trial Design
2d ago
NASDAQ.COM
Opus Genetics Added to Russell Indexes, Enhancing Market Visibility
Jun 26 2026
Newsfilter
Opus Genetics Updates on Gene Therapy Developments
Jun 17 2026
NASDAQ.COM
Wall Street's Latest Ratings and Price Target Adjustments
Jun 04 2026
CNBC
Opus Genetics Reports Q1 Losses and Revenue Decline
May 12 2026
seekingalpha
Opus Genetics Reports Vision Restoration Data in Pediatric Patients
May 07 2026
Newsfilter
Opus Genetics Receives FDA RDEP Designation for LCA5 Gene Therapy
May 05 2026
NASDAQ.COM
Opus Genetics' OPGx-LCA5 Accepted into FDA's Rare Disease Program
May 04 2026
Newsfilter
Opus Genetics to Present Three Studies at ASCRS Annual Meeting
Apr 10 2026
Newsfilter
Opus Genetics Presents New Research at ASCRS Meeting
Apr 10 2026
Yahoo Finance
Opus Genetics Secures $155 Million Financing Agreement
Apr 06 2026
seekingalpha
Opus Genetics Secures $155 Million Financing Agreement
Apr 06 2026
Newsfilter
Opus Genetics Reports 29.2% Revenue Growth in FY 2025
Mar 10 2026
seekingalpha
Opus Genetics Reports Positive Clinical Data for OPGx-BEST1 Therapy
Feb 27 2026
Newsfilter
Opus Genetics Receives FDA Review for New Drug Application
Feb 25 2026
Newsfilter
Show More News
